1. Identification and Optimization of a Novel HIV-1 Integrase Inhibitor. Adu-Ampratwum, D., Y. Pan, P.C. Koneru, J. Antwi, A.C. Hoyte, J. Kessl, P.R. Griffin, M. Kvaratskhelia, J.R. Fuchs, and R.C. Larue. ACS Omega, 2022. 7(5): p. 4482-4491. PMID[35155940]. PMCID[PMC8829933].
[PubMed]. HIV_02_2022.
2. Fluorine Modifications Contribute to Potent Antiviral Activity against Highly Drug-resistant HIV-1 and Favorable Blood-brain Barrier Penetration Property of Novel Central Nervous System-Targeting HIV-1 Protease Inhibitors in Vitro. Amano, M., R.S. Yedidi, P.M. Salcedo-Gómez, H. Hayashi, K. Hasegawa, C.D. Martyr, A.K. Ghosh, and H. Mitsuya. Antimicrobial Agents and Chemotherapy, 2022. 66(2): e0171521. PMID[34978889]. PMCID[PMC8846478].
[PubMed]. HIV_02_2022.
3. Engineered Zinc Finger Protein Targeting 2LTR Inhibits HIV Integration in Hematopoietic Stem and Progenitor Cell-Derived Macrophages: In Vitro Study. Chupradit, K., W. Khamaikawin, S. Sakkhachornphop, C. Puaninta, B.E. Torbett, S. Borwornpinyo, S. Hongeng, M. Wattanapanitch, and C. Tayapiwatana. International Journal of Molecular Sciences, 2022. 23(4): 2331. PMID[35216446]. PMCID[PMC8875109].
[PubMed]. HIV_02_2022.
4. Discovery of Novel Pyridine-dimethyl-phenyl-DAPY Hybrids by Molecular Fusing of Methyl-pyrimidine-DAPYs and Difluoro-pyridinyl-DAPYs: Improving the Druggability toward High Inhibitory Activity, Solubility, Safety, and PK. Ding, L., C. Pannecouque, E. De Clercq, C. Zhuang, and F.E. Chen. Journal of Medicinal Chemistry, 2022. 65(3): p. 2122-2138. PMID[35073089].
[PubMed]. HIV_02_2022.
5. Isolation, Synthesis, and Structure-Activity Relationship Study on Daphnane and Tigliane diterpenes as HIV Latency-reversing Agents. El-Desoky, A.H.H., K. Eguchi, N. Kishimoto, T. Asano, H. Kato, Y. Hitora, S. Kotani, T. Nakamura, S. Tsuchiya, T. Kawahara, M. Watanabe, M. Wada, M. Nakajima, T. Watanabe, S. Misumi, and S. Tsukamoto. Journal of Medicinal Chemistry, 2022. 65(4): p. 3460-3472. PMID[35113551].
[PubMed]. HIV_02_2022.
6. Structural Studies and Structure Activity Relationships for Novel Computationally Designed Non-nucleoside Inhibitors and Their Interactions with HIV-1 Reverse Transcriptase. Frey, K.M., N. Bertoletti, A.H. Chan, J.A. Ippolito, M. Bollini, K.A. Spasov, W.L. Jorgensen, and K.S. Anderson. Frontiers in Molecular Biosciences, 2022. 9: 805187. PMID[35237658]. PMCID[PMC8882919].
[PubMed]. HIV_02_2022.
7. Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages. Hany, L., M.O. Turmel, C. Barat, M. Ouellet, and M.J. Tremblay. Journal of Virology, 2022. 96(4): e0195321. PMID[34878918]. PMCID[PMC8865430].
[PubMed]. HIV_02_2022.
8. Development of Novel Dihydrofuro[3,4-d]pyrimidine Derivatives as HIV-1 NNRTIs to Overcome the Highly Resistant Mutant Strains F227L/V106A and K103N/Y181C. Kang, D., Y. Sun, D. Feng, S. Gao, Z. Wang, L. Jing, T. Zhang, X. Jiang, H. Lin, E. De Clercq, C. Pannecouque, P. Zhan, and X. Liu. Journal of Medicinal Chemistry, 2022. 65(3): p. 2458-2470. PMID[35061384].
[PubMed]. HIV_02_2022.
9. Synthesis and Evaluation of Acylated Derivatives of Hederagenin as Inhibitors of HIV-1 and HCV NS3/4A Proteases. Liu, Q., Y. Wei, Y.J. Hao, J. Yang, B.W. Pan, X.S. Yang, Y. Zhou, and X. Wang. Natural Product Communications, 2022. 17(1): 1934578x221075083. ISI[000752627700001].
[WOS]. HIV_02_2022.
10. Design and Synthesis of Leucylaniline Derivatives as Leucyl-tRNA Synthetase Inhibitors. Luo, J.H., C.J. Wu, Y.J. Hu, X.X. Jia, Y. Chen, and T.M. Sun. New Journal of Chemistry. 46: p. 4142-4155. ISI[000753028200001].
[WOS]. HIV_02_2022.
11. Pyridine/Pyrimidine Substituted Imidazol-5-one Analogs as HIV-1 RT Inhibitors: Design, Synthesis, Docking and Molecular Dynamic Simulation Studies. Mokale, S., D. Lokwani, and A. Mujaheed. Current HIV Research, 2021. 19(6): p. 535-547. PMID[34525923].
[PubMed]. HIV_02_2022.
12. Sulfated Polysaccharides from Seaweed Strandings as Renewable Source for Potential Antivirals against Herpes Simplex Virus 1. Pliego-Cortés, H., K. Hardouin, G. Bedoux, C. Marty, S. Cérantola, Y. Freile-Pelegrín, D. Robledo, and N. Bourgougnon. Marine Drugs, 2022. 20(2): 116. PMID[35200645]. PMCID[PMC8878361].
[PubMed]. HIV_02_2022.
13. C6-Structural Optimizations of 2-Aryl-1H-pyrazole-S-DABOS: From anti-HIV to anti-DENV Activity. Rui, R.M., C.R. Tang, C.T. Zhang, W.K. Pan, K. Gan, R.H. Luo, Z.Q. Wei, F.S. Jing, S.M. Huang, L.M. Yang, Y.M. Li, Y.P. Wang, W.L. Xiao, H.B. Zhang, Y.T. Zheng, and Y.P. He. Bioorganic Chemistry, 2022. 119: 105494. PMID[34836643].
[PubMed]. HIV_02_2022.
14. Design, Synthesis, Biological Evaluation, and Molecular Docking Study of Thioxo-2,3-dihydroquinazolinone Derivative as Tyrosinase Inhibitors. Sepehri, N., M. Khoshneviszadeh, S.M. Farid, S.S. Moayedi, M.S. Asgari, A. Moazzam, S. Hosseini, H. Adibi, B. Larijani, S. Pirhadi, M. Attarroshan, A. Sakhteman, M. Kabiri, H. Hamedifar, A. Iraji, and M. Mahdavi. Journal of Molecular Structure, 2022. 1253: 132283. PMID[000744670300002].
[WOS]. HIV_02_2022.
15. Anti-HIV Activity of Snake Venom Phospholipase A2s: Updates for New Enzymes and Different Virus Strains. Siniavin, A., S. Grinkina, A. Osipov, V. Starkov, V. Tsetlin, and Y. Utkin. International Journal of Molecular Sciences, 2022. 23(3): 1610. PMID[35163532]. PMCID[PMC8835987].
[PubMed]. HIV_02_2022.
16. Synthesis and Molecular Structure of 4-{[6-((2SR,4SR)-4-Acetyl-4-methylpyrrolidin-2-yl)-2-(4-cyanophenoxy)pyrimidin-4-yl]oxy}-3,5-dimethylbenzonitrile and 4-[(6-{(2SR,4SR)-4-Acetyl-1-[(4-bromophenyl)sulfonyl]-4-methylpyrrolidin-2-yl}-2-(4-cyanophenoxy)pyrimidin-4-yl)oxy]-3,5-dimethylbenzonitrile. Sokolov, N.A., V.N. Ivanov, I.R. Iusupov, A.V. Iasevich, A.V. Trubnikov, Y.V. Ulianova, K.A. Lyssenko, and A.V. Kurkin. Chemistry of Heterocyclic Compounds, 2022. 58: p. 64-67. ISI[000749585900002].
[WOS]. HIV_02_2022.
17. Cytotoxicity and anti-HIV Activities of Extracts of the Twigs of Croton dichogamus Pax. Terefe, E.M., F.A. Okalebo, S. Derese, G.E. Batiha, A. Youssef, M. Alorabi, and J. Muriuki. BMC Complementary Medicine and Therapies, 2022. 22(1): 49. PMID[35216601]. PMCID[PMC8876114].
[PubMed]. HIV_02_2022.
18. Pembrolizumab Induces HIV Latency Reversal in People Living with HIV and Cancer on Antiretroviral Therapy. Uldrick, T.S., S.V. Adams, R. Fromentin, M. Roche, S.P. Fling, P.H. Goncalves, K. Lurain, R. Ramaswami, C.C.J. Wang, R.J. Gorelick, J.L. Welker, L. O'Donoghue, H. Choudhary, J.D. Lifson, T.A. Rasmussen, A. Rhodes, C. Tumpach, R. Yarchoan, F. Maldarelli, M.A. Cheever, R. Sekaly, N. Chomont, S.G. Deeks, and S.R. Lewin. Science Translational Medicine, 2022. 14(629): eabl3836. PMID[35080914].
[PubMed]. HIV_02_2022.
19. Polyphenol Extracts from Grape Seeds and Apple Can Reactivate Latent HIV-1 Transcription through Promoting P-TEFb Release from 7SK snRNP. Wang, C., H. Wang, Z. Pan, J. Wu, Y. Guo, J. Zhang, Z. Xiang, W. Lu, and Y. Xue. Disease Markers, 2022. 2022: 6055347. PMID[35178129]. PMCID[PMC8843978].
[PubMed]. HIV_02_2022.
20. Supercoiling Structure-based Design of a Trimeric Coiled-coil Peptide with High Potency against HIV-1 and Human Β-Coronavirus Infection. Wang, C., S. Xia, X. Wang, Y. Li, H. Wang, R. Xiang, Q. Jiang, Q. Lan, R. Liang, Q. Li, S. Huo, L. Lu, Q. Wang, F. Yu, K. Liu, and S. Jiang. Journal of Medicinal Chemistry, 2022. 65(4): p. 2809-2819. PMID[33929200]. PMCID[PMC8117781].
[PubMed]. HIV_02_2022.
Patent Citations
This month, no relevant HIV patents were identified.